Time Restricted Eating in Patients with Microalbuminuria

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Mar 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how time-restricted eating (TRE) might help improve kidney health in people with type 2 diabetes who have a specific condition called microalbuminuria, where there is an increased amount of protein in the urine. Participants in the study will follow a daily eating schedule where they only eat during a set window of 8 to 10 hours. This trial is still in the planning stages and has not started recruiting participants yet.

To be eligible for this study, you need to be between 18 and 75 years old and have type 2 diabetes with certain blood sugar levels. You should also have a specific urine test result indicating microalbuminuria. It's important that you're able to walk independently and can use a smartphone for the study's procedures. Participants will maintain their current medications during the trial, with some exceptions. If you're interested, you can expect to follow the eating schedule and log your food intake through a smartphone app. Overall, this study aims to explore a simple dietary change that might make a difference in kidney health for people with diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age: 18-75 years old
• • 2. Participants with T2DM with A1c between 6.5 and 9.0 % and on stable doses of medications who are weight-bearing and self-ambulatory.
• • 3. uACR ( urine albumin creatinine ratio) results ≥ 30 - 300 mg.
• • 4. Willingness to use smartphone for research procedures (Apple iOS or Android OS)
• • 5. Baseline eating period ≥12 hours/day and sufficient logging on the mCC app.
• • 6. Person of childbearing potential will be given a pregnancy test on study enrollment and asked to use contraception throughout the study.
• • 7. Post-menopausal and individuals on hormone replacement therapy will be included.
• • 8. Estimated Glomerular Filtration Rate (EGFR) \> 45
• • 9. If participants are on cardiovascular medications (HMG CoA reductase inhibitors (statins), other lipid-modifying drugs, anti-hypertensives) no dose adjustments will be allowed during the study period
• • 10. Participants on stable doses (consistent dose for ≥3 months) of GLP-1 receptor agonists will be included.
• Exclusion Criteria:
• • 1. Participants with Type1DM and T2DM who are taking insulin, sulfonylureas, or have an HbA1c \> 9 %.
• • 2. Estimated Glomerular Filtration Rate (EGFR) \< 45
• • 3. Systolic BP greater than 160 mmHg and/or Diastolic BP greater than 110 mmHg (with or without treatment/medication)
• • 4. LDL cholesterol greater than 200 mg/dL
• • 5. Triglycerides greater than 500 mg/dL
• • 6. Active tobacco or illicit drug use
• • 7. Pregnant or breastfeeding individuals.
• • 8. Currently enrolled in a weight-loss or weight-management program,
• • 9. Currently on a special or prescribed diet for other reasons (e.g., Celiac disease),
• • 10. On recently prescribed medication that is meant for weight loss, or has known effect on appetite suppression ( patient on stable dose for 3 months can be enrolled ).
• • 11. History of eating disorder(s).
• • 12. History of surgical intervention for weight management (e) active eating disorder.
• • 13. Chronic kidney disease with an eGFR calculated based on the Modification of Diet in Renal Disease (MDRD) equation \<50mL/min/1.73m2
• • 14. Treatment for active inflammatory and/or rheumatologic disease and cancer.
• • 15. A major adverse cardiovascular event within the past 6 months such as acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA).
• • 16. History of Uncontrolled arrhythmia (i.e., rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria) 18. Liver cirrhosis and/or significant alterations in liver function
• • 17. History of (a) thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e., hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion), Shift workers with variable (e.g., nocturnal) hours.
• • 18. Caregivers for dependents requiring frequent nocturnal care/sleep interruptions.
• • 19. More than one trip planned to travel to a time zone with greater than a 3-hour difference during study period.
• • 20. History of major adverse cardiovascular events within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)).
• • 21. History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e., hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion).
• • 22. History of adrenal disease.
• • 23. History of malignancy undergoing active treatment, except non-melanoma skin cancer.
• • 24. Known history of type I diabetes.
• • 25. History of stage 4 or 5 chronic kidney disease or requiring dialysis.
• • 26. History of HIV/AIDS.
• • 27. Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness).